Prospective Assessment of Efficacy of Immunoadsorption Therapy in Managing Childhood NMDA-Receptor (NMDAR) Antibodies Encephalitis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of the study is to assess the efficacy of immunoadsorption therapy (IA) on improving the neurological status of severe pediatric anti-NMDAR encephalitis patients.
Eligibility
Participation Requirements
Sex: All
Maximum Age: 18
Healthy Volunteers: f
View:
• Age: 0-18 years inclusive
• Autoimmune encephalitis with positive anti-NMDAR antibodies in CSF (definite anti-NMDAR encephalitis according to Graus's criteria (Graus et al., 2016).
• PCPCS and mRS at 4 or over at the inclusion after first line therapy (steroids and/or IgIV) when Rituximab therapy is warranted
• Parents or legal guardians signed the Informed consent form
• Social insurance affiliation
Locations
Other Locations
France
Hôpital Necker Enfants-Malades
RECRUITING
Paris
Contact Information
Primary
Isabelle DESGUERRE, MD, PhD
isabelle.desguerre@aphp.fr
+33 1.44.49.41.42
Backup
Aminata TRAORE
aminata.traore6@aphp.fr
+33 1 48 19 27 34
Time Frame
Start Date: 2021-06-23
Estimated Completion Date: 2026-06
Participants
Target number of participants: 20
Treatments
Experimental: IA session
* 4 Rituximab injections~* 10 IA sessions
Related Therapeutic Areas
Sponsors
Leads: Assistance Publique - Hôpitaux de Paris